Business
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction
About this update from Xtl Biopharmaceuticals Ltd.
[{"type":"image","alt":"Beyond Air™","displaySize":"","headline":null,"caption":"Beyond Air™","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/283e6374c7eeb2f53ca652917eb5334d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cVMIN3hdiWRLf4negBQkjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/283e6374c7eeb2f53ca652917eb5334d","width":264,"height":50}},"lazy":false},{"type":"text","content":"Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher","length":117,"tagName":"p"},{"type":"text","content":"Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist","length":108,"tagName":"p"},{"type":"text","content":"FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma","length":103,"tagName":"p"},{"type":"text","content":"Platform targets the core biology of autism, not just symptomatic relief","length":72,"tagName":"p"},{"type":"text","content":"Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital","length":113,"tagName":"p"},{"type":"text","content":"Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments","length":99,"tagName":"p"},{"type":"text","content":"TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB.TA) today announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), a biotechnology company pioneering disease-modifying therapeutics targeting the core pathophysiology of Autism Spectrum Disorder (ASD) and neuro-oncology.","length":385,"tagName":"p"},{"type":"text","content":"This transformative acquisition positions XTL as a major player in the rapidly expanding autism therapeutics market, addressing one of the most urgent and underserved medical needs in global healthcare. Unlike symptomatic treatments, NeuroNOS's platform is designed to address the underlying molecular mechanisms driving autism.","length":332,"tagName":"p"},{"type":"text","content":"The Autism Crisis and Market Opportunity","length":40,"tagName":"p"},{"typ...